SL
IKT icon

Siren LLC’s Inhibikase Therapeutics IKT Stock Holding History

Siren LLC’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9M Hold
5,850,000
– – 0.24% 65
2026
Q1 		$9.83M Hold
5,850,000
– – 0.27% 58
2025
Q4 		$12M Buy
+5,850,000
New +$9.31M 0.36% 48

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Siren LLC's IKT Position: Q2 2026 in Review

Siren LLC held its Inhibikase Therapeutics (IKT) position steady in Q2 2026 at 5,850,000 shares worth $11.9M. The position accounts for 0.24% of the portfolio, ranked #65.

Siren LLC first reported a position in IKT in Q4 2025 and has held it in 3 quarters since. The position peaked at $12M in Q4 2025. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Siren LLC held 5,850,000 shares of Inhibikase Therapeutics worth $11.9M as of Q2 2026.
  • Siren LLC left its Inhibikase Therapeutics share count unchanged in Q2 2026.
  • Inhibikase Therapeutics made up 0.24% of Siren LLC's portfolio in Q2 2026, its #65 holding.
  • Siren LLC first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Siren LLC's Inhibikase Therapeutics position peaked at $12M in Q4 2025.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.